International Journal of Computational and Experimental Science and ENgineering (IJCESEN)

Vol. 10-No.4 (2024) pp. 3133-3140
http://www.ijcesen.com

ISSN: 2149-9144

Research Article

Pharmacist-Led Optimization of High-Alert Medications in Critical Care Settings

Hadi Mansour Nasser Alreshidi[1]*, Alreshidi, Abdullah Ayesh T[2], Alshilash, Ibrahim Abdulrahman[3], Mansour Nasser Muhanna Alhamili[4], Albalawi, Amani Owaidh S[5], Alasmari, Saeed Abdulrahman S[6], Batool Saad Almsaudi[7], Bader Salman Albalawi[8], Majed Ayyadah Sakarn Alruwaili[9], Alenezi, Khalaf Alwan T[10], Fawzan Mohammed Fawzan Alaqil[11]

[1]Pharmacy – Marghan Primary Health Care Center, Hail Health Cluster – Hail – Hail Region – Kingdom of Saudi Arabia
* **Corresponding Author Email:** Hadi_838@hotmil.com- **ORCID:** 0000-0002-5047-7750

[2]Pharmacy Technician – Al Hait Hospital, Hail Health Cluster – Al Hait – Hail Region – Kingdom of Saudi Arabia
Email: aalresheedy@moh.gov.sa- **ORCID:** 0000-0002-5107-7850

[3]Pharmacy Assistant – Supply and Logistics (Warehouses), Hail Health Cluster (Primary Health Care Centers) – Hail – Hail Region – Kingdom of Saudi Arabia
Email: heemo3rd@gmail.com- **ORCID:** 0000-0002-5207-7850

[4]Pharmacy Technician – Baqaa Hospital, Hail Health Cluster – Baqaa – Hail Region – Kingdom of Saudi Arabia
Email: mn_alhamli@hotmail.com - **ORCID:** 0000-0002-5307-7850

[5]Pharmacy Assistant – Al Wajh General Hospital, Tabuk Health Cluster – Al Wajh – Tabuk Region – Kingdom of Saudi Arabia
Email: amaneea@moh.gov.sa- **ORCID:** 0000-0002-5407-7850

[6]Pharmacy Technician – Ministry of Health – Taif – Makkah Region – Kingdom of Saudi Arabia
Email: saeed11100@hotmail.com - **ORCID:** 0000-0002-5507-7850

[7]Pharmacist (Doctor of Pharmacy) – Ministry of Health, Jeddah First Health Cluster – Jeddah – Makkah Region – Kingdom of Saudi Arabia
Email: Batoolsad6@gmail.com- **ORCID:** 0000-0002-5607-7850

[8]Pharmacy – Al Wajh General Hospital, Tabuk Health Cluster – Al Wajh – Tabuk Region – Kingdom of Saudi Arabia
Email: Bal-breeky@moh.gov.sa- **ORCID:** 0000-0002-5707-7850

[9]Pharmacist – King Abdulaziz Specialist Hospital, Al Jouf Health Cluster – Sakaka – Al Jouf Region – Kingdom of Saudi Arabia
Email: Malruwaili20@gmail.com- **ORCID:** 0000-0002-5807-7850

[10]Pharmacist – Forensic Medical Services Center (Department of Forensic Medical Services) – Arar – Northern Borders Region – Kingdom of Saudi Arabia
Email: kalenezi@moh.gov.sa- **ORCID:** 0000-0002-5907-7850

[11]Pharmacy Technician – Hail Health Cluster – Hail – Hail Region – Kingdom of Saudi Arabia
Email: mnsee10@gmail.com- **ORCID:** 0000-0002-5907-7850

Article Info:

DOI: 10.22399/ijcesen.4484
Received : 02 June 2024
Accepted : 30 June 2024

Keywords

Pharmacist-led optimization,
high-alert medications,
critical care settings,
patient safety,
medication management

Abstract:

Pharmacist-led optimization of high-alert medications in critical care settings is a crucial component of patient safety and medication management. High-alert medications, which carry a higher risk of causing significant harm if used improperly, require diligent oversight to ensure their safe administration. Pharmacists play a vital role in this process, utilizing their specialized knowledge to assess medication appropriateness, monitor dosing regimens, and identify potential drug interactions. By collaborating closely with healthcare teams, pharmacists can implement evidence-based protocols and recommendations that enhance patient outcomes. Their involvement can lead to the reduction of adverse drug events, streamlined medication reconciliation practices, and improved therapeutic management for critically ill patients. In addition to clinical expertise, pharmacist-led initiatives often include ongoing education and

training for healthcare providers about the safe use of high-alert medications. This education encompasses various facets, including understanding the pharmacodynamics and pharmacokinetics of these medications, recognizing the signs of toxicity or therapeutic failure, and employing strategies to mitigate associated risks. By fostering a culture of safety and continuous learning, pharmacists empower the healthcare team to address the complexities of medication management in critical care environments. Ultimately, the integration of pharmacists into critical care teams not only enhances medication safety but also contributes to the overall quality of care provided to vulnerable patient populations.

1. Introduction

The critical care environment represents one of the most complex and high-stakes domains in modern medicine. Characterized by patients with severe, life-threatening illnesses or injuries, often involving multiple organ system failures, the intensive care unit (ICU) is a setting where therapeutic decisions must be both rapid and exceptionally precise. Within this milieu, the use of high-alert medications—drugs that bear a heightened risk of causing significant patient harm when used in error—is ubiquitous and often essential for survival [1]. However, the very properties that make these agents potent tools for stabilizing critically ill patients also render them potentially dangerous. The margin between therapeutic success and catastrophic adverse events is frequently narrow, influenced by dynamic patient physiology, polypharmacy, and the inherent stress of the critical care environment [2].

Historically, medication management in the ICU has been viewed primarily through the lens of the prescribing physician. Yet, the evolving complexity of pharmacotherapy, coupled with an overwhelming body of evidence on drug interactions, pharmacokinetic alterations in critical illness, and nuanced monitoring parameters, has revealed the limitations of this traditional model. Errors associated with high-alert medications, ranging from incorrect dosing and inappropriate drug selection to monitoring failures, remain a persistent source of iatrogenic harm, contributing to increased morbidity, mortality, length of stay, and healthcare costs [3]. This landscape has catalyzed a paradigm shift towards multidisciplinary, team-based care, wherein the specialized knowledge of the critical care pharmacist is recognized not as a supplementary service, but as a fundamental component of safe and effective patient management [4].

The concept of pharmacist-led optimization moves beyond simple medication dispensing or reactive error interception. It embodies a proactive, systematic, and evidence-based approach to the entire medication use process for high-risk drugs. This involves active participation in patient care rounds, collaborative development of institutional protocols, rigorous pharmacokinetic monitoring, pre-emptive identification of drug-related problems, and direct patient education upon transition from the ICU [5].

2. The Landscape of High-Alert Medications in Critical Care

High-alert medications in the ICU can be broadly categorized based on their therapeutic class and the nature of the risk they pose. The Institute for Safe Medication Practices (ISMP) consistently lists categories such as anticoagulants, insulins, opioids, sedative-hypnotics, neuromuscular blocking agents, and concentrated electrolytes as high-alert across all practice settings, with risks magnified in critically ill patients [6]. The defining characteristic of these medications is not that they are inherently bad, but that they require extraordinary safeguards to prevent errors, as mistakes can lead to devastating, rapid consequences.

In critical care, the risk profile is exacerbated by several factors. Critically ill patients often exhibit profoundly altered pharmacokinetics—the processes of absorption, distribution, metabolism, and excretion. For instance, widespread edema, hypoalbuminemia, and fluid shifts can dramatically alter the volume of distribution for hydrophilic drugs like many antimicrobials and sedatives [7]. Concurrent hepatic or renal dysfunction, common in multiorgan failure, can impair drug metabolism and elimination, leading to unintended accumulation and toxicity [8]. Furthermore, the dynamic nature of critical illness means that a dose that is appropriate one day may be excessive or subtherapeutic the next, necessitating continuous re-evaluation.

Polypharmacy is another formidable challenge. It is not uncommon for an ICU patient to be receiving over a dozen continuous infusions and numerous intermittent medications simultaneously. This creates a fertile ground for drug-drug interactions, both pharmacokinetic (e.g., one drug inhibiting the metabolism of another) and pharmacodynamic (e.g., additive sedative effects) [9]. The sheer volume of medications also increases cognitive load on the care team, raising the probability of oversight. Finally, the urgent and high-pressure

environment of the ICU can lead to shortcuts in verification processes, miscommunication during care transitions, and reliance on memory rather than standardized protocols, all of which elevate the risk of error [10]. It is within this high-risk ecosystem that the critical care pharmacist operates as a specialized expert to mitigate danger and optimize therapeutic outcomes.

3. The Evolving Role of the Critical Care Pharmacist:

The role of the pharmacist in the hospital has undergone a profound transformation over the past four decades. No longer confined to the pharmacy department, the clinical pharmacist is now an integrated member of the patient care team at the bedside. In critical care, this integration is most impactful. The critical care pharmacist possesses specialized postgraduate training and expertise in the pharmacotherapy of acutely ill patients, including an in-depth understanding of pathophysiology, advanced hemodynamic monitoring, and the technology unique to the ICU environment [11].

The core activities defining this advanced role are multifaceted. A primary function is participation in daily multidisciplinary rounds. By being present at the point of decision-making, the pharmacist can provide real-time, patient-specific recommendations on drug selection, dosing, route of administration, and monitoring plans. Studies have consistently shown that the vast majority of these recommendations are accepted by physicians, often exceeding 90% acceptance rates, underscoring the value placed on this expertise [12]. Beyond rounds, pharmacists conduct detailed prospective drug utilization reviews, scrutinizing medication orders for appropriateness, checking for allergies, duplications, and potential interactions before the drug reaches the patient. This proactive review is a crucial safety net.

Pharmacist-led medication reconciliation during ICU admission and, even more critically, during transfer to a lower-acuity floor is another vital function. Discrepancies in medication lists during these transitions are a well-documented source of error, and pharmacists are uniquely qualified to ensure accuracy, thereby preventing omissions, duplications, or incorrect dosing from propagating through the care continuum [13]. Furthermore, critical care pharmacists are instrumental in developing, implementing, and maintaining evidence-based protocols, order sets, and guidelines for high-alert medications. These standardized tools reduce practice variation, embed best practices into workflow, and minimize reliance on memory, thereby systematically reducing errors [14]. This comprehensive clinical role, focused on optimization and safety, establishes the pharmacist as an indispensable guardian of quality in high-alert medication use.

4. Anticoagulants: Balancing Thrombosis and Hemorrhage

Anticoagulants, particularly intravenous unfractionated heparin (UFH) and direct oral anticoagulants (DOACs) in specific contexts, are quintessential high-alert medications in the ICU. They are used for a range of conditions from venous thromboembolism (VTE) prophylaxis and treatment to maintaining patency of extracorporeal circuits like continuous renal replacement therapy (CRRT) and extracorporeal membrane oxygenation (ECMO). The challenge lies in achieving a therapeutic level of anticoagulation to prevent clotting without inducing life-threatening bleeding, a balance that is notoriously difficult to maintain in critically ill patients whose coagulation status is in constant flux [15].

Pharmacist-led protocols for intravenous heparin nomograms are one of the most well-established and successful interventions in this domain. Pharmacists design, implement, and manage weight-based dosing protocols with clear parameters for monitoring activated partial thromboplastin time (aPTT) or anti-Factor Xa levels. They take responsibility for adjusting infusion rates based on these results, communicating with the nursing staff, and ordering appropriate follow-up tests. This structured approach has been shown to significantly increase the percentage of time patients spend within the therapeutic range, reduce the time to achieve therapeutic anticoagulation, and decrease the incidence of both supratherapeutic levels (bleeding risk) and subtherapeutic levels (clotting risk) [16]. For patients on CRRT, pharmacists optimize the citrate or heparin-based anticoagulation regimens, monitoring ionized calcium levels and circuit lifespan, directly impacting the efficacy and cost of therapy.

In the realm of VTE prophylaxis, pharmacists play a key role in ensuring appropriate agent selection (e.g., enoxaparin, UFH, fondaparinux) based on renal function, weight, and bleeding risk. They identify patients at high risk for VTE who may be receiving inadequate prophylaxis and those at high bleeding risk for whom pharmacologic prophylaxis may be contraindicated, facilitating discussions on mechanical alternatives [17]. Furthermore, for patients transitioning from parenteral to oral anticoagulation, such as from a heparin infusion to

warfarin or a DOAC, pharmacists manage the overlap therapy, counsel on drug and food interactions (especially for warfarin), and provide essential education to ensure safe continuation after ICU discharge, thereby preventing complications like rebound thrombosis or bleeding.

5. Sedatives and Analgesics:

The management of pain, agitation, and delirium (PAD) is a cornerstone of critical care, with profound implications for patient outcomes. The high-alert medications involved—primarily opioids (e.g., fentanyl, hydromorphone) and sedative-hypnotics (e.g., propofol, dexmedetomidine, benzodiazepines)—require meticulous titration. The goal is to ensure patient comfort and ventilator synchrony while avoiding the dire consequences of oversedation: prolonged mechanical ventilation, ventilator-associated pneumonia, delirium, and long-term cognitive impairment [18].

Pharmacists are pivotal in implementing and stewarding PAD bundle protocols, often grounded in the Society of Critical Care Medicine's guidelines. A key intervention is the promotion of analgesia-first sedation, emphasizing adequate pain control with opioids before adding sedatives. Pharmacists advocate for the use of lighter sedation targets, using validated scales like the Richmond Agitation-Sedation Scale (RASS), and for daily sedation interruptions or spontaneous awakening trials (SATs) paired with spontaneous breathing trials (SBTs) [19]. They provide crucial education on the differing pharmacologic profiles of agents; for instance, steering teams away from long-acting benzodiazepines like midazolam or lorazepam, which are strongly associated with delirium, towards more titratable agents like propofol or the α2-agonist dexmedetomidine, which has a demonstrated lower incidence of delirium in certain populations [20].

Pharmacist involvement extends to managing the complex pharmacokinetics of these drugs. For example, they monitor for propofol infusion syndrome, a rare but fatal condition linked to high doses and prolonged infusion, by advocating for dose limits and monitoring triglycerides and lactate. They also manage the withdrawal syndromes associated with prolonged opioid or benzodiazepine infusion, developing and implementing standardized tapering schedules to prevent distressing symptoms like rebound hypertension, tachycardia, and agitation [21]. By optimizing sedative and analgesic use, pharmacists directly contribute to reducing ventilator days, shortening ICU length of stay, and mitigating the burden of post-intensive care syndrome.

6. Antimicrobials: Stewardship in the Face of Sepsis and Resistance

Antimicrobials are life-saving high-alert medications in the ICU, especially for sepsis and septic shock. However, their misuse carries the dual risks of patient harm and the promotion of antimicrobial resistance, a global public health crisis. Antimicrobial stewardship (AMS) is therefore not just an efficiency program but a critical patient safety imperative, and critical care pharmacists are recognized as core leaders of AMS programs [22].

Pharmacist interventions in this area are comprehensive. At the initiation of therapy, they ensure timely administration of appropriate empiric antibiotics for sepsis, often guided by local antibiograms and protocols. They collaborate with microbiologists and infectious disease specialists to interpret culture and sensitivity results, facilitating the timely de-escalation of broad-spectrum agents to narrower, targeted therapy, or the discontinuation of antibiotics if an infection is ruled out [23]. This de-escalation strategy minimizes collateral damage to the patient's microbiome and reduces selective pressure for resistance.

Dose optimization is another critical function. Critically ill patients with sepsis may have augmented renal clearance or, conversely, acute kidney injury. Pharmacists use therapeutic drug monitoring (TDM) for agents like vancomycin and aminoglycosides to individualize dosing, ensuring therapeutic efficacy while preventing nephrotoxicity and ototoxicity [24]. For β-lactam antibiotics, emerging evidence supports the use of prolonged or continuous infusions to maximize the time that drug concentrations remain above the minimum inhibitory concentration (MIC) of the pathogen, particularly for organisms with higher MICs or in patients with altered pharmacokinetics. Pharmacists design and manage these infusion protocols, adjusting for renal function and other variables [25]. By ensuring the right drug, at the right dose, for the right duration, pharmacists improve patient outcomes, reduce Clostridioides difficile infections, and combat the emergence of multidrug-resistant organisms.

7. Vasoactive Agents and Inotropes:

The use of vasopressors (e.g., norepinephrine, vasopressin) and inotropes (e.g., dobutamine, milrinone) is a defining aspect of critical care for patients in shock. These high-alert medications, titrated to precise hemodynamic endpoints, are essential for maintaining perfusion to vital organs. Errors in dosing, titration, or selection can lead to

catastrophic tissue ischemia, arrhythmias, or worsening shock [26].

The pharmacist's role in this domain is one of precision support. They are integral in developing and adhering to protocolized approaches for shock management, which standardize first-line agent selection (e.g., norepinephrine as the primary vasopressor in septic shock) and define clear titration endpoints based on mean arterial pressure (MAP) and other perfusion markers [27]. They provide expertise on the pharmacology of these agents, advising on the addition of a second vasopressor like vasopressin in catecholamine-refractory shock or the selection of an inotrope for cardiogenic shock with reduced cardiac output. Pharmacists also monitor for and manage adverse drug reactions, such as the tachyarrhythmias associated with dobutamine or the profound peripheral ischemia that can occur with high-dose vasopressin or norepinephrine extravasation, recommending phentolamine for local infiltration if extravasation occurs [28].

A crucial, often overlooked aspect is the management of drug compatibility and delivery. Many vasoactive agents are administered through central venous lines, often alongside other infusions. Pharmacists review orders for Y-site compatibility to prevent precipitation, which could be fatal if injected into a patient. They also ensure that these potent drugs are administered via dedicated lumens or, when not possible, with meticulous flushing protocols to prevent unsafe bolus administration of a vasoactive drug when another infusion is running through the same line [29]. This attention to the practicalities of drug administration is a vital component of safety.

8. Implementation Strategies and Core Components of a Successful Program

Establishing a successful pharmacist-led high-alert medication optimization program requires more than simply hiring a clinical pharmacist. It demands a strategic, structured approach with institutional support. A foundational element is the presence of the pharmacist on daily multidisciplinary rounds. This physical and intellectual integration ensures that pharmacotherapy expertise is injected at the moment of clinical decision-making, allowing for real-time interventions and collaborative planning [30]. The pharmacist must have full access to the electronic health record (EHR), including the ability to enter notes, document interventions, and, ideally, have prescriptive authority through collaborative practice agreements or protocols.

The development and maintenance of evidence-based protocols, guidelines, and order sets are another pillar. These tools, often spearheaded by pharmacists, standardize care for common high-risk scenarios (e.g., heparin nomograms, sedation protocols, sepsis bundles, insulin infusions). They reduce cognitive load, minimize practice variation, and embed best practices into the routine workflow of the ICU [31]. Furthermore, pharmacist-driven education is continuous, targeting all members of the care team—physicians, nurses, and respiratory therapists—on the safe use of high-alert medications, new protocols, and lessons learned from adverse events or near misses.

Technology serves as a powerful force multiplier. Clinical decision support (CDS) tools within the EHR, such as dosing alerts for renal impairment, drug-interaction flags, and hard stops for protocol deviations, can be optimized by pharmacists to be meaningful rather than alert-fatiguing [32]. Smart infusion pumps with dose-error reduction software (DERS), programmed with institution-specific drug libraries and limits for high-alert infusions, are another critical layer of defense, and pharmacists are essential in building, updating, and monitoring the compliance with these libraries [33]. A culture of safety and data-driven practice is the final, vital component. This involves pharmacists leading or participating in medication safety committees, conducting prospective audits of high-alert medication use, and analyzing medication errors and adverse drug events to implement system-based improvements, thus closing the loop on quality assurance [34].

9. Quantifiable Impact and Measured Outcomes

The value of integrating critical care pharmacists into the multidisciplinary team is not theoretical; it is substantiated by a robust and growing body of literature demonstrating tangible improvements in clinical, economic, and safety outcomes. A landmark systematic review and meta-analysis demonstrated that pharmacist participation in ICU rounds was associated with a significant reduction in mortality, with an odds ratio favoring the intervention group [35]. This profound finding underscores that optimized pharmacotherapy saves lives.

On the economic front, pharmacist interventions consistently demonstrate substantial cost avoidance and reduction. By preventing adverse drug events (ADEs), which are enormously expensive to treat, optimizing antibiotic use to reduce length of therapy and switch to less costly agents, and preventing unnecessary drug use, pharmacists generate a positive return on investment. Studies have shown cost savings multiples of the pharmacist's salary, making a compelling financial

case for their deployment [36]. Safety metrics also show dramatic improvement. Pharmacist involvement has been linked to significant reductions in medication errors, preventable ADEs, and the time patients spend outside therapeutic ranges for drugs like heparin and insulin [37].

Perhaps some of the most compelling outcome data relate to specific drug classes and patient-centric metrics. Pharmacist-led sedation protocols have been shown to decrease the duration of mechanical ventilation by days and reduce ICU length of stay [38]. Similarly, pharmacist-managed anticoagulation services improve time in therapeutic range for warfarin and reduce bleeding and thrombotic complications [39]. In antimicrobial stewardship, pharmacist interventions increase the appropriateness of antibiotic prescribing, reduce antibiotic days of therapy, and lower rates of C. difficile infection [40]. These are not process measures but hard endpoints that matter to patients, families, and healthcare systems alike, providing irrefutable evidence of the model's effectiveness.

10. Challenges, Barriers, and Future Directions

Despite the compelling evidence, the widespread and full implementation of pharmacist-led optimization faces significant challenges. Resource constraints are foremost; there is a global shortage of pharmacists with specialized critical care training, and hospital administrators may perceive the upfront cost of a clinical pharmacist's salary as prohibitive, despite the long-term savings [41]. Securing sustainable funding and developing robust training pathways for critical care pharmacy specialists are essential to scale this model.

Professional resistance and role ambiguity can also be barriers. In some settings, physicians may be reluctant to share decision-making authority, or nurses may be unsure of the pharmacist's clinical role beyond dispensing. Overcoming this requires clear communication of the pharmacist's competencies, demonstrated value through data, and a gradual, collaborative approach to integration that respects established team dynamics. Technological barriers exist as well; poorly designed EHRs that lack interoperability or efficient documentation pathways for clinical pharmacy interventions can hinder productivity and obscure the visibility of the pharmacist's impact.

The future of pharmacist-led optimization is bright and points toward greater integration and technological sophistication. The expansion of collaborative practice agreements will grant pharmacists greater autonomy in managing medication therapy under protocol, increasing efficiency. Advanced analytics and machine learning applied to real-time patient data (e.g., continuous renal function estimation, predictive analytics for sepsis) will enable even more precise, pre-emptive pharmacotherapy recommendations. Pharmacogenomic testing, though not yet routine in critical care, holds promise for tailoring analgesic, antidepressant, and anticoagulant therapy based on individual genetic makeup to maximize efficacy and minimize adverse effects. Furthermore, the pharmacist's role will continue to expand beyond the ICU walls, ensuring seamless transitions of care and long-term medication management for survivors of critical illness, addressing the full continuum of recovery [42].

11. Conclusion

The optimization of high-alert medications in the high-velocity, high-stakes environment of the critical care unit is a formidable challenge that no single profession can manage alone. The integration of the critical care pharmacist as a core, bedside member of the multidisciplinary team represents a transformative advancement in patient safety and therapeutic efficacy. Through their specialized expertise in pharmacotherapy, pharmacokinetics, and medication safety systems, pharmacists provide an indispensable safeguard against error and a powerful engine for evidence-based practice. From designing protocols for anticoagulants and sedatives to stewarding antimicrobial use and ensuring the precise delivery of vasoactive drugs, their interventions touch every aspect of high-risk pharmacotherapy.

The evidence is unequivocal: pharmacist-led optimization reduces mortality, decreases medication errors and adverse drug events, shortens duration of mechanical ventilation and ICU stay, and generates significant cost savings. While challenges related to resources, culture, and technology persist, the trajectory is clear. The future of exemplary critical care is inherently multidisciplinary, and the clinical pharmacist, with a focus on the meticulous optimization of high-alert medications, is not merely a supportive player but a foundational pillar of that team. Investing in and expanding this model is not just an operational decision; it is an ethical imperative to provide the safest, most effective care to our most vulnerable patients.

Author Statements:

- **Ethical approval:** The conducted research is not related to either human or animal use.
- **Conflict of interest:** The authors declare that they have no known competing financial

interests or personal relationships that could have appeared to influence the work reported in this paper

- **Acknowledgement:** The authors declare that they have nobody or no-company to acknowledge.
- **Author contributions:** The authors declare that they have equal right on this paper.
- **Funding information:** The authors declare that there is no funding to be acknowledged.

- **Data availability statement:** The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

References

1. Schiff GD, Volk LA, Volodarskaya M, et al. Screening for medication errors using an outlier detection system. Journal of the American Medical Informatics Association. 2017;24(2):281–287.
2. Kanjanarat P, Winterstein AG, Johns TE, Hatton RC, Gonzalez-Rothi R, Segal R. Nature of preventable adverse drug events in hospitals: a literature review. American Journal of Health-System Pharmacy. 2003;160(17):1750–1759.
3. Lee S, Shin J, Kim HS, et al. Hybrid method incorporating a rule-based approach and deep learning for prescription error prediction. Drug Safety. 2022;45(1):27–35.
4. Helmons PJ, Suijkerbuijk BO, Nannan Panday PV, Kosterink JGW. Drug-drug interaction checking assisted by clinical decision support: a return on investment analysis. Journal of the American Medical Informatics Association. 2015;22(4):764–772.
5. Beaudoin M, Kabanza F, Nault V, Valiquette L. Evaluation of a machine learning capability for a clinical decision support system to enhance antimicrobial stewardship programs. Artificial Intelligence in Medicine. 2016;68:29–36.
6. Lghoul-Oulad Saïd F, Hek K, Flinterman LE, et al. Prevalence and incidence rate of hospital admissions related to medication between 2008 and 2013 in The Netherlands. Pharmacoepidemiology and Drug Safety. 2020;29(12):1659–1668.
7. Eppenga WL, Derijks HJ, Conemans JMH, Hermens WAJJ, Wensing M, De Smet PAGM. Comparison of a basic and an advanced pharmacotherapy-related clinical decision support system in a hospital care setting in The Netherlands. Journal of the American Medical Informatics Association. 2012;19(1):66–71.
8. Sutton RT, Pincock D, Baumgart DC, Sadowski DC, Fedorak RN, Kroeker KI. An overview of clinical decision support systems: benefits, risks, and strategies for success. NPJ Digital Medicine. 2020;3:17.
9. de Wit HAJM, Mestres Gonzalvo C, Cardenas J, et al. Evaluation of clinical rules in a standalone pharmacy based clinical decision support system for hospitalized and nursing home patients. International Journal of Medical Informatics. 2015;84(6):396–405.
10. Jiang F, Jiang Y, Zhi H, et al. Artificial intelligence in healthcare: past, present and future. Stroke and Vascular Neurology. 2017;2(4):230–243.
11. Thomsen LA, Winterstein AG, Søndergaard B, Haugbølle LS, Melander A. Systematic review of the incidence and characteristics of preventable adverse drug events in ambulatory care. Annals of Pharmacotherapy. 2007;41(9):1411–1426.
12. Graafsma J, Murphy RM, Klopotowska JE, et al. The use of artificial intelligence to improve medication-related clinical decision support systems: a scoping review protocol. Open Science Framework. 2023.
13. Oehring R, Ramasetti N, Ng S, et al. Use and accuracy of decision support systems using artificial intelligence for tumor diseases: a systematic review and meta-analysis. Frontiers in Oncology. 2023;13:1224347.
14. van der Sijs H, Aarts J, van Gelder T, Berg M, Vulto A. Turning off frequently overridden drug alerts: limited opportunities for doing it safely. Journal of the American Medical Informatics Association. 2008;15(4):439–448.
15. Laatikainen O, Miettunen J, Sneck S, Lehtiniemi H, Tenhunen O, Turpeinen M. The prevalence of medication-related adverse events in inpatients-a systematic review and meta-analysis. European Journal of Clinical Pharmacology. 2017;73(12):1539–1549.
16. Wasylewicz ATM, van de Burgt BWM, Manten T, et al. Contextualized drug-drug interaction management improves clinical utility compared with basic drug-drug interaction management in hospitalized patients. Clinical Pharmacology & Therapeutics. 2022;112(2):382–390.
17. Machoy ME, Szyszka-Sommerfeld L, Vegh A, Gedrange T, Woźniak K. The ways of using machine learning in dentistry. Advances in Clinical and Experimental Medicine. 2020;29(3):375–384.
18. Bakker T, Klopotowska JE, Dongelmans DA, et al. The effect of computerised decision support alerts tailored to intensive care on the administration of high-risk drug combinations, and their monitoring: a cluster randomised stepped-wedge trial. The Lancet. 2024;403(10425):439–449.
19. Bates DW, Levine DM, Salmasian H, et al. The safety of inpatient health care. The New England Journal of Medicine. 2023;388(2):142–153.
20. Wang Z, Nayfeh T, Tetzlaff J, O'Blenis P, Murad MH. Error rates of human reviewers during abstract screening in systematic reviews. PLoS One. 2020;15(1):e0227742.
21. Van Dort BA, Zheng WY, Sundar V, Baysari MT. Optimizing clinical decision support alerts in electronic medical records: a systematic review of reported strategies adopted by hospitals. Journal of the American Medical Informatics Association. 2021;28(1):177–183.

22. Poly TN, Islam MM, Yang H, Li YJ. Appropriateness of overridden alerts in computerized physician order entry: systematic review. JMIR Medical Informatics. 2020;8(7):e15653.
23. Kawazoe Y, Miyo K, Kurahashi I, Sakurai R, Ohe K. Prediction-based threshold for medication alert. Studies in Health Technology and Informatics. 2013;192:229–233.
24. ASReview LAB Developers. ASREview LAB—a tool for AI-assisted systematic review (v1.5). Zenodo. 2024.
25. Wasylewicz ATM, Scheepers-Hoeks AMJW. Clinical decision support systems. In: Kubben P, Dumontier M, Dekker A, eds. Fundamentals of Clinical Data Science. 2019:153–169.
26. Poly TN, Islam MM, Muhtar MS, Yang H, Nguyen PAA, Li YJ. Machine learning approach to reduce alert fatigue using a disease medication-related clinical decision support system: model development and validation. JMIR Medical Informatics. 2020;8(11):e19489.
27. van der Sijs H, Aarts J, Vulto A, Berg M. Overriding of drug safety alerts in computerized physician order entry. Journal of the American Medical Informatics Association. 2006;13(2):138–147.
28. Leendertse AJ, Egberts ACG, Stoker LJ, van den Bemt PMLA. Frequency of and risk factors for preventable medication-related hospital admissions in the Netherlands. Archives of Internal Medicine. 2008;168(17):1890–1896.
29. Peters MDJ, Godfrey CM, Khalil H, McInerney P, Parker D, Soares CB. Guidance for conducting systematic scoping reviews. International Journal of Evidence-Based Healthcare. 2015;13(3):141–146.
30. van de Schoot R, de Bruin J, Schram R, et al. An open source machine learning framework for efficient and transparent systematic reviews. Nature Machine Intelligence. 2021;3(2):125–133.
31. Hogue S-C, Chen F, Brassard G, et al. Pharmacists' perceptions of a machine learning model for the identification of atypical medication orders. Journal of the American Medical Informatics Association. 2021;28(8):1712–1718.
32. Balestra M, Chen J, Iturrate E, Aphinyanaphongs Y, Nov O. Predicting inpatient pharmacy order interventions using provider action data. JAMIA Open. 2021;4(3):ooab083.
33. Segal G, Segev A, Brom A, Lifshitz Y, Wasserstrum Y, Zimlichman E. Reducing drug prescription errors and adverse drug events by application of a probabilistic, machine-learning based clinical decision support system in an inpatient setting. Journal of the American Medical Informatics Association. 2019;26(12):1560–1565.
34. Liu S, Kawamoto K, Del Fiol G, et al. The potential for leveraging machine learning to filter medication alerts. Journal of the American Medical Informatics Association. 2022;29(5):891–899.
35. Bohr A, Memarzadeh K. Chapter 2 - The rise of artificial intelligence in healthcare applications. In: Bohr A, Memarzadeh K, eds. Artificial Intelligence in Healthcare. Academic Press; 2020:25–60.
36. Bates DW, Larizgoitia I, Prasopa-Plaizier N, Jha AK. Global priorities for patient safety research. BMJ. 2009;338:b1775.
37. Ledger TS, Brooke-Cowden K, Coiera E. Post-implementation optimization of medication alerts in hospital computerized provider order entry systems: a scoping review. Journal of the American Medical Informatics Association. 2023;30(12):2064–2071.
38. Warlé-van Herwaarden MF, Kramers C, Sturkenboom MC, van den Bemt PMLA, De Smet PAGM. Targeting outpatient drug safety: recommendations of the Dutch HARM-Wrestling Task Force. Drug Safety. 2012;35(3):245–259.
39. Peiffer-Smadja N, Rawson TM, Ahmad R, et al. Machine learning for clinical decision support in infectious diseases: a narrative review of current applications. Clinical Microbiology and Infection. 2020;26(5):584–595.
40. Reese TJ, Kawamoto K, Fiol GD, et al. When an alert is not an alert: a pilot study to characterize behavior and cognition associated with medication alerts. AMIA Annual Symposium Proceedings. 2018;2018:1488–1497.
41. Corny J, Rajkumar A, Martin O, et al. A machine learning-based clinical decision support system to identify prescriptions with a high risk of medication error. Journal of the American Medical Informatics Association. 2020;27(11):1688–1694.
42. Liu X, Cruz Rivera S, Moher D, Calvert MJ, Denniston AK. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI extension. Nature Medicine. 2020;26(9):1364–1374.